Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Gianfranco Ferraccioli, Monika M. Schoels, Désirée Van Der Heijde, Ferdinand C. Breedveld, Gerd R. Burmester, Maxime Dougados, Paul Emery, Cem Gabay, Allan Gibofsky, Juan Jesus Gomez-Reino, Graeme Jones, Tore K. Kvien, Miho M. Murikama, Norihiro Nishimoto, Josef S. Smolen

Risultato della ricerca: Contributo in rivistaArticolo in rivista

64 Citazioni (Scopus)

Abstract

Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.
Lingua originaleEnglish
pagine (da-a)583-589
Numero di pagine7
RivistaEARD
Volume72
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Arthritis, Juvenile
  • Arthritis, Rheumatoid
  • Consensus
  • Humans
  • Interleukin-6
  • Spondylitis, Ankylosing

Fingerprint Entra nei temi di ricerca di 'Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement'. Insieme formano una fingerprint unica.

Cita questo